Human VEGF 121 Recombinant Protein

Also known as: Vascular endothelial growth factor

RUO: For Research Use Only. Not for use in diagnostic procedures.

SKU# 14-8359

Cat. No. Size
14-8359-62 5 ug
14-8359-80 25 ug

To enable ordering, please select your country. Cookies will need to be enabled to continue on our website. View our Privacy Policy.

Data for Human VEGF Recombinant Protein.

Description

Description: Vascular endothelial growth factor (VEGF), also called vascular permeability factor (VPF), is produced by cultured vascular smooth muscle cells. From analysis of transcripts from these cells by PCR and cDNA cloning, 3 different forms of the VEGF coding region have been identified. These cDNAs had predicted products of 189, 165, and 121 amino acids. VEGF is a mitogen primarily for vascular endothelial cells. It is structurally related to platelet-derived growth factor. VEGF, a homodimeric glycoprotein of relative molecular mass 45,000, is the only mitogen that specifically acts on endothelial cells. The VEGF receptor, Flk1, is exclusively expressed in endothelial cells. VEGF may be a major regulator of tumor angiogenesis in vivo.

Details
Reactivity Human
Purity Greater than 98% as determined by SDS-PAGE
Molecular Mass The protein is not methionylated at the N-terminal and has a predicted molecular mass of 14,071. The DTT reduced protein migrates as a 14 kDa doublet on SDS-PAGE. The cystine-linked homodimer migrates as a 29 kDa protein on non-reduced SDS-PAGE.
Endotoxin Level Less than 0.01 ng/ug cytokine as determined by the LAL assay.
Reported Applications Cytokine Bioassays
Documentation

For complete product information, please download the TDS or IFU document.

TDS Link Download TDS
Additional Formats
Cat. No. Name Excite Emit Application Reg.
34-8359 Human VEGF 121 Recombinant Protein Carrier-Free FA RUO
References

References: Tischer, E., et al. 1991. The human gene for vascular endothelial growth factor: multiple protein forms are encoded through alternative exon splicing. J. Biol. Chem. 266: 11947-11954.
Millauer, B., et al. 1994. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367: 576-579. Folkman, J. 1995. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med. 1: 27-31.